SG11202001647UA - Conjugate of vegf-grab protein and drug, and use thereof - Google Patents
Conjugate of vegf-grab protein and drug, and use thereofInfo
- Publication number
- SG11202001647UA SG11202001647UA SG11202001647UA SG11202001647UA SG11202001647UA SG 11202001647U A SG11202001647U A SG 11202001647UA SG 11202001647U A SG11202001647U A SG 11202001647UA SG 11202001647U A SG11202001647U A SG 11202001647UA SG 11202001647U A SG11202001647U A SG 11202001647UA
- Authority
- SG
- Singapore
- Prior art keywords
- vegf
- conjugate
- drug
- grab protein
- grab
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Animal Husbandry (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20170083747 | 2017-06-30 | ||
PCT/KR2018/007465 WO2019004799A1 (en) | 2017-06-30 | 2018-07-02 | Conjugate of vegf-grab protein and drug, and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202001647UA true SG11202001647UA (en) | 2020-03-30 |
Family
ID=64742515
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202001647UA SG11202001647UA (en) | 2017-06-30 | 2018-07-02 | Conjugate of vegf-grab protein and drug, and use thereof |
Country Status (9)
Country | Link |
---|---|
US (1) | US20200148757A1 (en) |
EP (1) | EP3646887A4 (en) |
JP (2) | JP2020532282A (en) |
KR (1) | KR102124142B1 (en) |
CN (1) | CN111032092A (en) |
AU (1) | AU2018290633B9 (en) |
CA (1) | CA3068635A1 (en) |
SG (1) | SG11202001647UA (en) |
WO (1) | WO2019004799A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3743091A4 (en) | 2018-01-26 | 2021-12-15 | The Regents of the University of California | Methods and compositions for treatment of angiogenic disorders using anti-vegf agents |
US20220135651A1 (en) * | 2019-02-18 | 2022-05-05 | Agency For Science, Technology And Research | A membrane-bound fit-1 decoy and uses thereof |
CA3134680C (en) * | 2019-03-29 | 2024-02-06 | Green Cross Corporation | Fusion protein comprising anti-mesothelin antibody, anti-cd3 antibody or anti-egfr antibody, bispecific or trispecific antibody comprising same, and uses thereof |
WO2020242220A1 (en) * | 2019-05-28 | 2020-12-03 | 울산과학기술원 | Fusion protein containing protein having target cell or target protein binding ability of specifically binding to glutathione-s-transferase and vascular endothelial growth factor, vascular endothelial growth factor receptor, or tumor necrosis factor-alpha, and use thereof |
CN112552410A (en) * | 2019-09-26 | 2021-03-26 | 三生国健药业(上海)股份有限公司 | Antibody fusion protein, preparation method thereof and application thereof in anti-tumor |
WO2021108255A1 (en) | 2019-11-25 | 2021-06-03 | The Regents Of The University Of California | Long-acting vegf inhibitors for intraocular neovascularization |
KR102337471B1 (en) * | 2019-12-23 | 2021-12-09 | 한국프라임제약주식회사 | A pharmaceutical formulation comprising VEGFR fusion protein |
US20230159663A1 (en) * | 2020-04-24 | 2023-05-25 | Virtuoso Binco, Inc. | Bispecific antibodies for treating cd47-associated diseases |
KR20230131448A (en) * | 2022-03-04 | 2023-09-13 | 주식회사 파노로스바이오사이언스 | Composition For Combi-Therapy Comprising VEGF-Grab and PD-1 or PD-L1 Antagonist |
WO2024029876A1 (en) * | 2022-08-02 | 2024-02-08 | 주식회사 파노로스바이오사이언스 | Modified fusion protein and use thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030075947A (en) | 2002-03-19 | 2003-09-26 | 제네티카 주식회사 | Angiogenesis inhibitor |
EP1767546B1 (en) * | 2004-06-08 | 2012-03-07 | Chengdu Kanghong Biotechnologies Co., Ltd. | Angiogenesis-inhibiting chimeric protein and the use |
JP5096142B2 (en) | 2004-07-30 | 2012-12-12 | メチルジーン インコーポレイテッド | Inhibitors of VEGF receptor and HGF receptor signaling |
KR101397088B1 (en) * | 2011-06-10 | 2014-05-19 | 강원대학교산학협력단 | A fusion protein for inhibiting both angiogenesis and tumor cell proliferation, and composition comprising the same |
CA2902830C (en) * | 2013-03-12 | 2023-09-19 | Biocon Ltd. | Fusion immunomodulatory proteins and methods for making same |
SG10201707548RA (en) * | 2013-03-19 | 2017-10-30 | Toppan Printing Co Ltd | Method for predicting sensitivity to egfr inhibitor |
DK3042669T3 (en) * | 2013-09-06 | 2023-06-12 | Taiho Pharmaceutical Co Ltd | ANTI-TUMOR AGENT AND AMPLIFIER OF ANTI-TUMOR EFFECT |
RU2675824C2 (en) * | 2013-09-11 | 2018-12-25 | Игл Байолоджикс, Инк. | Liquid protein formulations containing ionic liquids |
KR101844596B1 (en) * | 2014-03-18 | 2018-04-05 | 한국과학기술원 | Compositions for Treating Eye Disease comprising Glycosylated VEGF Decoy Receptor Fusion Protein |
KR20180012832A (en) * | 2015-06-28 | 2018-02-06 | 올제네시스 바이오테라퓨틱스 아이엔씨. | Fusion protein for angiogenesis inhibition |
KR101685532B1 (en) * | 2016-04-26 | 2016-12-13 | 한국프라임제약주식회사 | A VEGFR fusion protein |
-
2018
- 2018-07-02 CN CN201880055304.4A patent/CN111032092A/en active Pending
- 2018-07-02 KR KR1020180076694A patent/KR102124142B1/en active IP Right Grant
- 2018-07-02 AU AU2018290633A patent/AU2018290633B9/en active Active
- 2018-07-02 WO PCT/KR2018/007465 patent/WO2019004799A1/en active Application Filing
- 2018-07-02 CA CA3068635A patent/CA3068635A1/en active Pending
- 2018-07-02 US US16/625,707 patent/US20200148757A1/en not_active Abandoned
- 2018-07-02 EP EP18823953.7A patent/EP3646887A4/en active Pending
- 2018-07-02 JP JP2020500132A patent/JP2020532282A/en active Pending
- 2018-07-02 SG SG11202001647UA patent/SG11202001647UA/en unknown
-
2021
- 2021-10-13 JP JP2021168113A patent/JP7348249B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2018290633B2 (en) | 2021-03-25 |
EP3646887A1 (en) | 2020-05-06 |
CA3068635A1 (en) | 2019-01-03 |
KR20190003931A (en) | 2019-01-10 |
JP7348249B2 (en) | 2023-09-20 |
JP2020532282A (en) | 2020-11-12 |
JP2022028654A (en) | 2022-02-16 |
EP3646887A4 (en) | 2021-03-24 |
US20200148757A1 (en) | 2020-05-14 |
AU2018290633A1 (en) | 2020-01-30 |
CN111032092A (en) | 2020-04-17 |
WO2019004799A1 (en) | 2019-01-03 |
KR102124142B1 (en) | 2020-06-18 |
AU2018290633B9 (en) | 2021-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11202001647UA (en) | Conjugate of vegf-grab protein and drug, and use thereof | |
PT3546457T (en) | Pyrazolo-heteroaryl derivative, preparation method and medical use thereof | |
HK1257056A1 (en) | Anti-dll3 antibody drug conjugates and methods of use | |
ZA201900470B (en) | Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof | |
HK1255566A1 (en) | Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof | |
EP3284751A4 (en) | Anti-c-met antibody and anti-c-met antibody-cytotoxic drug conjugate and pharmaceutical use thereof | |
EP3354661A4 (en) | Fully human antibody against human cd137 and use thereof | |
EP3491026A4 (en) | Human antibodies, pharmaceutical compositions and methods | |
IL285148A (en) | Bi-ligand drug conjugate and use thereof | |
IL272446A (en) | Substituted penta- fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof | |
EP3632907C0 (en) | N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof | |
IL275190A (en) | Anti-cd22 antibody-maytansine conjugates, combinations, and methods of use thereof | |
EP3617218A4 (en) | Dihydroartemisinin-steroid conjugate and preparation method and use thereof | |
EP3721890A4 (en) | Ophthalmic drug preparation and uses thereof | |
EP3560517A4 (en) | Aptamer-drug conjugate and use thereof | |
IL272571A (en) | Nr4a1 ligands, pharmaceutical compositions, and related methods of use | |
EP3495348A4 (en) | Guanidine derivative and use thereof for medical purposes | |
IL272920A (en) | Anti-egfr antibody drug conjugates (adc) and uses thereof | |
IL272050B1 (en) | Synthetic proteins and therapeutic uses thereof | |
EP3600439A4 (en) | Modified oligonucleotides and therapeutic uses thereof | |
EP3266870A4 (en) | Conjugate and use thereof | |
IL274177A (en) | Therapeutic substances, their preparation and diagnostic procedure | |
ZA202000959B (en) | Adamantylmethylamine derivative and use thereof as pharmaceutical | |
EP3310786A4 (en) | Drug delivery and imaging chemical conjugate, formulations and methods of use thereof | |
IL259712B (en) | Stable dosage form of etidronate-cytarabine conjugate, and use thereof |